Mameghan H, Fisher R J, Watt W H, Meagher M J, Rosen I M, Mameghan J, Brook S, Tynan A P, Korbel E I, Millard R J
Department of Radiation Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.
Cancer. 1992 Jun 1;69(11):2771-8. doi: 10.1002/1097-0142(19920601)69:11<2771::aid-cncr2820691124>3.0.co;2-d.
The treatment results for invasive transitional cell carcinoma (TCC) of the bladder were assessed in a series of 390 patients referred to the Department of Radiation Oncology at the Prince of Wales Hospital, Sydney, Australia, during the period 1977 to 1988. These patients were managed by one of two strategies: cystectomy (87 patients) and radiation therapy (303 patients). Actuarial survival rates (death from any cause) were determined and comparisons were made using log-rank tests and Cox regression analyses. The mean follow-up time was 7.6 years. Independent prognostic factors for shorter survival were: the presence of a ureteric obstruction (P less than 0.001), increasing clinical stage (P less than 0.001), increasing patient age (P = 0.003), and earlier year of presentation (P = 0.008). Comparison of the two strategies indicated no significant difference in overall survival after adjusting for imbalances in prognostic factors (P = 0.007 unadjusted; P = 0.29 adjusted). The slightly longer survival of 46 patients from 1983 onward who received primary systemic chemotherapy (compared with 149 patients not given chemotherapy) was not statistically significant (P = 0.12 unadjusted; P = 0.56 adjusted for prognostic factors). The 5-year actuarial rates of severe complications were 8.0% after cystectomy and 5.3% after radiation therapy. In 303 patients treated by definitive radiation therapy, the 5-year actuarial rate of freedom from bladder failure for all clinical tumor stages was 44% (Tx, 67%; T1, 45%; T2, 56%; T3, 39%; and T4, 39%). These results suggest that definitive radiation therapy is a viable alternative to radical cystectomy for patients with invasive TCC of the bladder.
1977年至1988年期间,澳大利亚悉尼威尔士亲王医院放射肿瘤学系对390例浸润性膀胱移行细胞癌(TCC)患者的治疗结果进行了评估。这些患者采用两种策略之一进行治疗:膀胱切除术(87例患者)和放射治疗(303例患者)。确定了精算生存率(任何原因导致的死亡),并使用对数秩检验和Cox回归分析进行比较。平均随访时间为7.6年。生存时间较短的独立预后因素为:输尿管梗阻(P<0.001)、临床分期增加(P<0.001)、患者年龄增加(P=0.003)以及就诊年份较早(P=0.008)。两种策略的比较表明,在调整预后因素不平衡后,总生存率无显著差异(未调整P=0.007;调整后P=0.29)。1983年以后接受一线全身化疗的46例患者(与149例未接受化疗的患者相比)生存时间略长,但无统计学意义(未调整P=0.12;根据预后因素调整后P=0.56)。膀胱切除术后严重并发症的5年精算发生率为8.0%,放射治疗后为5.3%。在303例接受根治性放射治疗的患者中,所有临床肿瘤分期的5年膀胱无失败精算发生率为44%(Tx期,67%;T1期,45%;T2期,56%;T3期,39%;T4期,39%)。这些结果表明,对于浸润性膀胱TCC患者,根治性放射治疗是根治性膀胱切除术的可行替代方案。